Silo Pharma announced results from its non-GLP small animal dose-ranging study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder. The purpose of the non-GLP small animal study was to identify the maximum tolerated intranasal dose of the drug pharmacokinetic and determine the therapeutically relevant dose range to be studied in clinical trials. Data analysis demonstrated rapid absorption of SPC-15 with good exposure over a 24-hour period, suggesting a once-per-day human intranasal dosing regimen would be optimal.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SILO:
- Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
- Silo Pharma says SP-26 ketamine implant demonstrates ‘successful’ drug delivery
- Silo Pharma Prioritizes Mental Health in 2024 Pipeline
- Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
- Silo Pharma preparing pre-IND application for lead drug program SPC-15
